Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWARE aztreonam-avibactam real-world study in MBL-producing CRE infections
ChiCTR2500109207Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aztreonam + avibactam in complicated intra-abdominal infection (cIAI), Hospital-acquired pneumonia caused by carbapenem-resistant Enterobacterales (CRE-HAP) and ventilator-associated pneumonia (VAP), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Clinical response at end of treatment. Started Sep 2025; status: recruiting.
02
Drugs
aztreonam + avibactam
03
Conditions
complicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia caused by carbapenem-resistant Enterobacterales (CRE-HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on ChiCTR2500109207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109207.